Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive advanced ALK plus non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study

被引：5
|
作者：
Zhou, C. [1 ]
Lu, Y. [2 ]
Kim, S-W. [3 ]
Baisamut , T. [4 ]
Zhou, J. [5 ]
Zhang, Y. [6 ]
He, J. [7 ]
Yang, J. [8 ]
Cheng, Y. [9 ]
Lee, S-H. [10 ]
Chang, J. [11 ]
Fang, J. [12 ]
Liu, Z. [13 ]
Bu, L. [14 ]
Qian, L. [15 ]
Xu, T. [15 ]
Archer, V. [16 ]
Hilton, M. [17 ]
Zhou, M. [18 ]
Zhang, L. [19 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Thorac Oncol, Chengdu, Peoples R China
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Mahidol Univ, Fac Med, Ramathibodi Hosp, Bangkok, Thailand
[5] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China
[6] Zhejiang Canc Hosp, Dept Thorac Oncol, Hangzhou, Peoples R China
[7] Guangzhou Med Univ, Dept Thorac Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[8] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[9] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[11] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Canc Hosp, Shenzhen, Peoples R China
[12] Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[13] Capital Med Univ, Beijing Chest Hosp, Dept Oncol, Beijing, Peoples R China
[14] Roche Pharma Dev, Dept Data Sci, Shanghai, Peoples R China
[15] Roche Pharma Dev, Dept Clin Sci, Shanghai, Peoples R China
[16] Roche Prod Ltd, Prod Dev, Welwyn Garden City, Herts, England
[17] F Hoffmann La Roche Ltd, Prod Dev Data Sci, Basel, Switzerland
[18] Roche Pharma Dev, Dept Safety, Shanghai, Peoples R China
[19] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA11
引用
收藏
页码：S1563 / S1563
页数：1
相关论文
共 50 条
  • [21] Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
    Scagliotti, G.
    Kim, T. M.
    Crino, L.
    Liu, G.
    Gridelli, C.
    Novello, S.
    Kiura, K.
    Bearz, A.
    Gautschi, O.
    Felip, E.
    Nishio, M.
    Spigel, D. R.
    Mok, T. S. K.
    Urban, P.
    Deudon, S.
    Zheng, C.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC
    Mok, T. S. K.
    Shaw, A. T.
    Camidge, R. D.
    Gadgeel, S. M.
    Rosell, R.
    Dziadziuszko, R.
    Kim, D-W.
    Perol, M.
    Ou, S-H.
    Bordogna, W.
    Smoljanovic, V.
    Hilton, M.
    Peters, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 607 - 607
  • [23] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Kim, E.
    Usari, T.
    Polli, A.
    Lewis, I.
    Wilner, K.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
  • [24] Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC).
    Solomon, Benjamin J.
    Bauer, Todd Michael
    Felip, Enriqueta
    Liu, Geoffrey
    Mazieres, Julien
    De Marinis, Filippo
    Goto, Yasushi
    Kim, Dong-Wan
    Laktionov, Konstantin K.
    Blackhall, Fiona Helen
    Dall'O, Elisa
    Polli, Anna
    Toffalorio, Francesca
    Mok, Tony S. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naive anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Halawah, Hala
    Calamia, Matthias
    Gulick, Dexter
    Manasrah, AlMothana
    Alkhdour, Odai
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] INDIRECT TREATMENT COMPARISON OF ALECTINIB VS. BRIGATINIB IN ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Wong, W.
    Sheinson, D.
    VALUE IN HEALTH, 2019, 22 : S59 - S59
  • [27] Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial
    Ou, Sai-Hong Ignatius
    Tiseo, Marcella
    Camidge, D. Ross
    Ahn, Myung-Ju
    Huber, Rudolf M.
    Hochmair, Maximilian J.
    Kim, Sang-We
    West, Howard Jack
    Reckamp, Karen L.
    Molina, Julian R.
    Liu, Geoffrey
    Delmonte, Angelo
    Ramirez, Santiago Viteri
    Bearz, Alessandra
    Summers, Yvonne J.
    Reichmann, William
    Kerstein, David
    Gettinger, Scott N.
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Phase II study of Crizotinib in East Asian patients (pts) with ROS1+ advanced non-small cell lung cancer (NSCLC)
    Goto, Koichi
    Yang, James C. H.
    Kim, Dong-Wan
    Lu, Shun
    Zhou, Jianying
    Seto, Takashi
    Yang, Jin-Ji
    Paolini, Jolanda
    Roychowdhury, Debasish
    Wu, Yi-Long
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK plus advanced non-squamous non-small cell lung cancer (NSCLC).
    Lu, Shun
    Mok, Tony
    Lu, You
    Zhou, Jianying
    Shi, Yuankai
    Sriuranpong, Virote
    Ho, James C. M.
    Ong, Choo Khoon
    Tsai, Chun-Ming
    Chung, Chin-Hee
    Wilner, Keith D.
    Tang, Yiyun
    Masters, Elizabeth
    Selaru, Paulina
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC.
    Peters, Solange
    Mok, Tony S. K.
    Gadgeel, Shirish M.
    Rosell, Rafael
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Perol, Maurice
    Ou, Sai-Hong Ignatius
    Shaw, Alice Tsang
    Bordogna, Walter
    Smoljanovic, Vlatka
    Hilton, Magalie
    Ruf, Thorsten
    Archer, Venice Rosale
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345